Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies

Next Previous
Trial Profile

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Tisagenlecleucel (Primary)
  • Indications Diffuse large B cell lymphoma; Haematological malignancies; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 03 Dec 2018 Planned End Date changed from 1 Jun 2028 to 1 Jul 2028.
    • 03 Dec 2018 Planned primary completion date changed from 1 Jun 2028 to 1 Jul 2028.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top